HOXA5: A Potential Drug Target for Various Diseases (G3202)

Target Name: HOXA5

NCBI ID: G3202

HOXA5

HOXA5: A Potential Drug Target for Various Diseases

Homo box A5 (HOXA5) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 6 and encodes a protein known as HoxA5, which is a key regulator of cell growth and differentiation.

HOXA5 is a transmembrane protein that plays a critical role in the development and maintenance of tissues and organs, including blood vessels, nervous system cells, and epithelial cells. It is involved in the regulation of cell proliferation, cell survival, and cell-cell adhesion, and is thought to be involved in the development of many diseases.

One of the key functions of HOXA5 is its ability to induce cell death, either through apoptosis or through a process called necroptosis. This cell death is regulated by the HOXA5 protein, which can induce cell death by activating various cellular stress pathways, including the production of reactive oxygen species (ROS) and the formation of mitochondrial stress granules.

HOXA5 is also involved in the regulation of cell migration and the development of tissues and organs. It has been shown to play a role in the regulation of angiogenesis, the formation of new blood vessels, and the development of cancer.

In addition to its role in cell biology, HOXA5 is also a potential drug target. The HOXA5 gene has been targeted by various researchers for potential drug development due to its involvement in cell death and regulation. HOXA5 has been shown to be a promising target for small molecule inhibitors, with several studies indicating that inhibitors of HOXA5 have the potential to treat various diseases.

One of the most promising HOXA5 inhibitors is a small molecule called FN-187, which is currently being developed by a company called Genoptix. FN-187 is a pan- inhibitor of HOXA5, which means that it inhibits the activity of all HOXA5 proteins, including HOXA5 itself.

In preclinical studies, FN-187 has been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, FN-187 has been shown to be effective in treating neuroblastoma, a type of cancer that affects young children, by inhibiting the activity of HOXA5 and causing cell death.

Another promising HOXA5 inhibitor is a small molecule called JS-2126, which is being developed by a company called BioCancellate. JS-2126 is a targeted inhibitor of HOXA5 that is designed to selectively inhibit the activity of HOXA5 in cancer cells.

In preclinical studies, JS-2126 has been shown to be effective in treating various cancers, including breast cancer, lung cancer, and colon cancer. It has been shown to cause a significant reduction in the growth of cancer cells and to inhibit the formation of new blood vessels that can contribute to the growth and spread of cancer.

In conclusion, HOXA5 is a gene that has been identified as a potential drug target and biomarker for various diseases. Its involvement in cell biology and its potential as a drug target make it an attractive target for small molecule inhibitors. The development of small molecule inhibitors of HOXA5, such as FN-187 and JS-2126, is an promising area of research that may lead to the development of new treatments for a variety of diseases.

Protein Name: Homeobox A5

Functions: Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Also binds to its own promoter. Binds specifically to the motif 5'-CYYNATTA[TG]Y-3'

The "HOXA5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HOXA5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets